---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012807"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:52:09.138095+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded

## Summary
- Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
- Cash $34.7M at Dec 31, 2025 vs $22.4M at Dec 31, 2024; operating expenses $15.5M incl $1.2M stock-based comp.
- Awarded U.S. Department of Veterans Affairs contract for EsoGuard with $1,938 Medicare-aligned pricing across 170 VA medical centers.
- Largest real-world esophageal precancer detection study (nearly 12,000 patients) shows EsoCheck 95% technical success rate and 95% procedures under two minutes.

## SEC filing metadata
- accession: 0001493152-26-012807
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/0001493152-26-012807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012807
- JSON: https://secwatch.observer/filing/0001493152-26-012807.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012807.txt

## Key facts
- Earnings Releases
  Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.
  - Period: fourth quarter and full year ended December 31, 2025
  - Revenue: $1.5 million
  - Net income: approximately $16.3 million or $(0.12) per common share
  - EPS: $(0.12) per common share
  - Result: reported results
  source text: --- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/0001493152-26-012807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.